Insight Molecular Diagnostics (IMDX) Income towards Parent Company (2015 - 2026)

Insight Molecular Diagnostics has reported Income towards Parent Company for 12 years, with the latest figure at -$11.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 43.72% year-over-year to -$11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.1 million (up 8.45% YoY) and the FY2025 annual result came in at -$59.7 million, up 52.45% from the prior year.
• Income towards Parent Company rose to -$11.2 million in Q1 2026 per IMDX's latest filing, from -$23.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$2.9 million in Q1 2023 and troughed at -$33.9 million in Q4 2024.
• A 5-year average of -$12.4 million and a median of -$8.1 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company soared 57.46% in 2023, then sank 212.0% in 2024.
• Over 5 years, Income towards Parent Company stood at -$33.0 million in 2022, then jumped by 91.12% to -$2.9 million in 2023, then plunged by 1058.78% to -$33.9 million in 2024, then increased by 29.91% to -$23.8 million in 2025, then surged by 52.69% to -$11.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$11.2 million, -$23.8 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.